Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Report of six cases with mast cell leukemia and a literature review].
Zhu F, Yu Y, Chen CY, Duan WB, Jiang Q, Yan R, Sun Y, Han YQ, Zhang J, Wang H, Zhang QR, Chen SN, Yan WH, Cai MJ, Zhang ZB, Yin J, Wang Q. Zhu F, et al. Among authors: duan wb. Zhonghua Nei Ke Za Zhi. 2024 Oct 1;63(10):996-1000. doi: 10.3760/cma.j.cn112138-20240401-00209. Zhonghua Nei Ke Za Zhi. 2024. PMID: 39375119 Review. Chinese.
The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
Duan W, Liu X, Jia J, Wang J, Gong L, Jiang Q, Zhao T, Wang Y, Zhang X, Xu L, Zhao X, Qin Y, Shi H, Chang Y, Huang X, Jiang H. Duan W, et al. Br J Haematol. 2021 Jan;192(2):265-271. doi: 10.1111/bjh.16745. Epub 2020 Jun 25. Br J Haematol. 2021. PMID: 32588434 Free article.
Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
Duan W, Liu X, Zhao X, Jia J, Wang J, Gong L, Jiang Q, Zhao T, Wang Y, Zhang X, Xu L, Shi H, Chang Y, Liu K, Huang X, Qin Y, Jiang H. Duan W, et al. Ann Hematol. 2021 May;100(5):1203-1212. doi: 10.1007/s00277-021-04432-z. Epub 2021 Jan 20. Ann Hematol. 2021. PMID: 33474629
[The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
Jia YJ, Liu H, Wang LR, Wang T, Feng R, Chen YJ, Wang M, Guo HX, Wen L, Duan WB, Yang YZ, Wang FR, Chen YY, Huang XJ, Lu J. Jia YJ, et al. Among authors: duan wb. Zhonghua Nei Ke Za Zhi. 2020 May 1;59(5):347-352. doi: 10.3760/cma.j.cn112138-20191217-00821. Zhonghua Nei Ke Za Zhi. 2020. PMID: 32370462 Chinese.
64 results